Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

AcnePsoriasis

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

J Eur Acad Dermatol Venereol

Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, Smith CH, Warren RB, BADBIR Study Group

doi: 10.1111/jdv.20739

Psoriatic Arthritis

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

Br J Dermatol

Graier T, Bordag N, Weger W, Laschober N, Ratzinger G, Jonak C, Prillinger K, Müllegger R, Mlynek A, Lange-Asschenfeldt B, Häring N, Hoetzenecker W, Posch C, Ellersdorfer C, Sator P, Gruber B, Hofer A, Gruber-Wackernagel A, Legat FJ, Großschädl K, Gruber V, Schadelbauer E, Repelnig M, Gressenberger P, Widnig A, Falkensteiner K, Salmhofer W, Wolf P

doi: 10.1093/bjd/ljaf394

Systemic Lupus Erythematosus

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

Arthritis Res Ther

Kojima K, Ichinose K, Umeda M, Shimizu T, Sato S, Suzuki T, Nakashima Y, Okada A, Horai Y, Fujikawa K, Aramaki T, Miyashita T, Furuyama M, Matsuoka N, Kawakami A

doi: 10.1186/s13075-025-03581-0

Autoimmune Disease

The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established conventional synthetic DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study

Rheumatology (Oxford)

Ablewhite J, Nakafero G, Almayahi A, Bechman K, Ahmed A, Davidson A, De Vere H, Dhillon E, Foulkes A, Gullick N, Heaton R, Hider S, Kyle S, Nowak K, Rose-Parfitt E, Ryan S, Tan SY, Wood N, Zebate G, Parsons K, Holmes J, Twohigg H, Reynolds JA, Mercer L, Galloway J, Abhishek A

doi: 10.1093/rheumatology/keag031

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Psoriasis

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

J Am Acad Dermatol

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T

doi: 10.1016/j.jaad.2025.11.033

Psoriasis

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis

JAMA Dermatol

Schwarz CW, Loft N, Bryld LE, Nissen CV, Ajgeiy KK, Bertelsen T, Hjuler KF, Dam TN, Iversen L, Rasmussen MK, Skov L

doi: 10.1001/jamadermatol.2025.5205

Psoriasis

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

J Eur Acad Dermatol Venereol

Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, Bansal A, Dahale SS, Martin R, Paguet B, Magnolo N, Kingo K

doi: 10.1111/jdv.70155

Psoriasis

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis

J Eur Acad Dermatol Venereol

Merola JF, Guenther L, Lynde C, Papp KA, Parish LC, Yamauchi P, Cheng S, Amouzadeh H, Deignan C, Jardon S, Chen M, Pinter A

doi: 10.1111/jdv.70110

Related content

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established conventional synthetic DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis